Health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation and treated with isatuximab, lenalidomide, bortezomib, and dexamethasone (Isa-RVd) versus rvd alone: Results from part 1 of the GMMG-HD7 study

K. Mai, Elias; Bertsch, Uta; Fenk, Roland; Besemer, Britta; Boquoi, Amelie; Schroers, Roland; von Metzler, Ivana; Hänel, Mathias; Mann, Christoph; Leypoldt, Lisa; Heilmeier, Bernhard; Huhn, Stefanie; Scheid, Christof; Wolfgang Blau, Igor; Luntz, Steffen; A.W. Holderried, Tobias; Trautmann-Grill, Karolin; Gezer, Deniz; Klaiber-Hakimi, Maika; Mueller, Martin; Shumilov, Evgenii; Michel, Christian; Geer, Thomas; Riesenberg, Hendrik; Lutz, Christoph; Raab, Marc; Hoffmann, Martin; Comerford, Erin; Kyheng, Maeva; Lin, Feng; Rhoten, Stephanie; Lavrova, Tatiana; Salwender, Hans; Weisel, Katja; Goldschmidt, Hartmut

doi:10.1182/blood-2025-2263

Public

Health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation and treated with isatuximab, lenalidomide, bortezomib, and dexamethasone (Isa-RVd) versus rvd alone: Results from part 1 of the GMMG-HD7 study

Shared by NobleBlocks on Nov 3, 2025 • 12:00 AM UTC

Authors:

Elias K. Mai

Uta Bertsch

Roland Fenk

Abstract

Abstract Introduction. In newly diagnosed multiple myeloma (NDMM) patients (pts) eligible for autologous stem-cell transplant (ASCT), the phase 3 GMMG-HD7 trial (NCT03617731) Part 1 demonstrated that isatuximab, lenalidomide, bortezomib and dexamethasone (Isa-RVd) induction significantly improved mi...

Subject

Medicine

Multiple myeloma

Lenalidomide

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!